All three principal cancer waiting-time standards in England were below their targets in August 2026, with the weakest performance on the two-month route from urgent referral to first treatment. The figures were analysed in an update published on 12 October; the underlying official statistics had been released on 9 October.
Three standards, three missed targets
The faster diagnosis standard measures whether someone referred urgently with suspected cancer is told within 28 days either that cancer has been diagnosed or that it has been ruled out. In August, 78.6% received that outcome in time, against an 80% target. The shortfall was 1.4 percentage points. An analysis of the figures estimated that meeting the target would have meant about 3,900 more people receiving an on-time outcome that month.
The 62-day standard follows an urgent referral through diagnosis to the start of first treatment. Performance was 71.9%, compared with an 85% target, a gap of 13.1 percentage points. That standard has not been met since December 2015. The analysis estimated that roughly 3,700 additional people would have started treatment within this standard in August if the target had been achieved. These are estimates of the difference implied by the target, not a separate count of people whose care was delayed solely because of a single service failure.
The 31-day measure covers the time from a decision to treat, or the earliest clinically appropriate date, to the start of first or subsequent treatment. It was met by 92.1% of patients, against a 96% target. The gap was 3.9 percentage points; the corresponding estimate was about 2,100 more people treated on time if this standard had been met.
Long waits remain a distinct concern
Within the 62-day pathway, 8.9% of people, around 1,400, waited more than 104 days after an urgent suspected cancer referral before beginning treatment in August. That figure describes an extended wait within a defined referral route; it should not be read as evidence that every person in this group had the same cancer, clinical circumstances or treatment plan.
Nor do headline percentages describe the whole experience of diagnosis and care. The measures track different points in the pathway: getting a diagnostic outcome, moving from urgent referral to first treatment, and starting treatment after a decision has been made. They have different clocks, targets and populations, so they cannot be added together or treated as interchangeable measures of one queue.
The 62-day measure also covers a broader set of referral routes than it did before these standards were revised in October 2023. It includes urgent suspected-cancer referrals, breast symptomatic referrals, urgent screening referrals and consultant upgrades. The 31-day measure includes subsequent treatment as well as first treatment. These changes matter when comparing current figures with older series.
Targets set against a 2029 commitment
The results leave a sizeable distance between current performance and the required levels, especially on the 62-day pathway. The National Cancer Plan for England, published in February 2026, commits the health service to meeting all cancer waiting-time targets by 2029. Its stated measures include improving productivity, making use of expanded diagnostic capacity and directing funding to Cancer Alliances to help providers improve performance.
Missing a target does not by itself establish what happened in an individual case or prove that a particular wait changed a patient’s outcome. Cancer pathways can require different investigations and treatment preparation, and services may prioritise people with more aggressive disease. The performance figures are nevertheless a system-level warning: in August, the majority met each standard, but all three remained short of the national threshold, and the largest gap was between urgent referral and first treatment.
For people worried about symptoms, the figures are not a reason to delay seeking help. The waiting-time standards apply after referral and measure service performance; an individual assessment and clinical advice remain the appropriate guide to care.
